Adalimumab is a human monoclonal antibody against TNF-alpha. It is produced by recombinant DNA technology using a mammalian cell expression system. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons.
Humira showed very potent, dose-dependent inhibition of IL-8 levels (IC50 = 0.00534 nM), whereas BIRB 796 and RV1088 did not reach 50% inhibition at the concentrations tested where cell viability was unaffected.
This patient was prescribed two doses of Humira, to reduce levels of TNFα.
All currently existing anticancer therapies involving TNF are targeted towards the ligand, TNF itself, which includes administration of very high doses of exogenous TNF for melanoma treatment – or use of soluble receptors and/or various forms of TNF antibodies (Remicade, Humira) and a soluble TNF receptor fusion protein (Enbrel) , .
All patients were treated with adalimumab (Humira) subcutaneous, at standard doses as it follows: 160 mg at week 0.80 mg at week 2 and afterwards 40 mg at a 2 week interval.